

CDKN2A mutations, there were significantly higher total numbers of mutations in their genome than in the tumors without *CDKN2A* mutation. No significant differences were found in the mutation load depending on whether tumors had mutations in B-Raf proto-oncogene, serine/threonine kinase gene (*BRAF*) or NRAS proto-oncogene, GTPase gene (*NRAS*). The study found that 11 of 19 *CDKN2A* carriers responded to immunotherapy, with 6 of the 19 *CDKN2A* carriers (32%) having a complete response, which is a significantly higher

frequency than that observed in the clinical trials. The authors speculate that patients with *CDKN2A*-mutated melanoma may have improved immunotherapy responses on account of increased mutational load, resulting in more neoantigens and stronger antitumor immune responses.

Helgadóttir H, Ghiorzo P, van Doorn R, et al. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline *CDKN2A* mutations [e-pub ahead of print]. *J Med Genet*. <https://doi.org/10.1136/jmedgenet-2018-105610>. Accessed December 20, 2018.

JAAD Game Changers:

Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study



Eden Lake, MD
Maywood, Illinois

Capsule Summary

- Pyoderma gangrenosum is a painful ulcerating disease. The current evidence base for treatment is limited.
- In a large prospective study of topical treatments, 44% of patients were healed by 6 months. Ulcer size was a predictor of healing, and 15% of patients with pyoderma gangrenosum had a recurrence.
- Clobetasol propionate 0.05% is a potentially useful first-line therapy for patients with pyoderma gangrenosum, particularly for patients with small lesions.

How did this article change the practice of dermatology?

Although this treatment is often given in clinical practice, this study confirms that high-potency topical steroids for solitary and small pyoderma gangrenosum lesions is an appropriate first-line therapy with 44% of patients healing by 6 months. Larger ulcerations might need more intensive therapy.

Funding sources: None

Conflicts of interest: None disclosed

Accepted for publication December 31, 2018.

Correspondence to: Eden Lake, MD, Dermatology Division, Loyola University Medical Center, 321 N La Grange Rd, La Grange Park, IL 60526-5622. E-mail: Eden.Lake@lumc.edu.

© 2018 by the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2018.11.003>

REFERENCE

1. Thomas KS, Ormerod AD, Craig FE, et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. *J Am Acad Dermatol*. 2016;75(5):940-949.